Thiotepa-based Conditioning Pre-Allo SCT

Phase 1 Trial of Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

What's the purpose of the trial?

This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
Trial status

Not yet accepting

Phase
Phase 1
Enrollment
48
Last Updated

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
  • Thiotepa is an antineoplastic chemotherapy agent that is used to treat several different kinds of cancer.
  • Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body, and may be used in the treatment of many different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Cohort 1: T1FluBu2 (low-intensity)

Not yet accepting

Cohort 2: T2FluBu2 (high-intensity)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.